Unknown

Dataset Information

0

A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.


ABSTRACT: Epstein-Barr virus (EBV) is tightly associated with certain human cancers, but there is as yet no specific treatment against EBV-related diseases. The EBV-encoded EBNA1 protein is essential to maintain viral episomes and for viral persistence. As such, EBNA1 is expressed in all EBV-infected cells, and is highly antigenic. All infected individuals, including individuals with cancer, have CD8(+) T cells directed towards EBNA1 epitopes, yet the immune system fails to detect and destroy cells harboring the virus. EBV immune evasion depends on the capacity of the Gly-Ala repeat (GAr) domain of EBNA1 to inhibit the translation of its own mRNA in cis, thereby limiting the production of EBNA1-derived antigenic peptides presented by the major histocompatibility complex (MHC) class I pathway. Here we establish a yeast-based assay for monitoring GAr-dependent inhibition of translation. Using this assay we identify doxorubicin (DXR) as a compound that specifically interferes with the GAr effect on translation in yeast. DXR targets the topoisomerase-II-DNA complexes and thereby causes genomic damage. We show, however, that the genotoxic effect of DXR and various analogs thereof is uncoupled from the effect on GAr-mediated translation control. This is further supported by the observation that etoposide and teniposide, representing another class of topoisomerase-II-DNA targeting drugs, have no effect on GAr-mediated translation control. DXR and active analogs stimulate, in a GAr-dependent manner, EBNA1 expression in mammalian cells and overcome GAr-dependent restriction of MHC class I antigen presentation. These results validate our approach as an effective high-throughput screening assay to identify drugs that interfere with EBV immune evasion and, thus, constitute candidates for treating EBV-related diseases, in particular EBV-associated cancers.

SUBMITTER: Voisset C 

PROVIDER: S-EPMC3974454 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.

Voisset Cécile C   Daskalogianni Chrysoula C   Contesse Marie-Astrid MA   Mazars Anne A   Arbach Hratch H   Le Cann Marie M   Soubigou Flavie F   Apcher Sébastien S   Fåhraeus Robin R   Blondel Marc M  

Disease models & mechanisms 20140220 4


Epstein-Barr virus (EBV) is tightly associated with certain human cancers, but there is as yet no specific treatment against EBV-related diseases. The EBV-encoded EBNA1 protein is essential to maintain viral episomes and for viral persistence. As such, EBNA1 is expressed in all EBV-infected cells, and is highly antigenic. All infected individuals, including individuals with cancer, have CD8(+) T cells directed towards EBNA1 epitopes, yet the immune system fails to detect and destroy cells harbor  ...[more]

Similar Datasets

| S-EPMC6096924 | biostudies-literature
| S-EPMC2832755 | biostudies-literature
| S-EPMC8782528 | biostudies-literature
| S-EPMC5504353 | biostudies-literature
| S-EPMC1805610 | biostudies-literature
| PRJNA794826 | ENA
| S-EPMC2603334 | biostudies-other
| S-EPMC4577157 | biostudies-literature
| S-EPMC3930590 | biostudies-literature
| S-EPMC10372749 | biostudies-literature